Stephen Kennedy is the Chief Operating Officer and Executive VP of Histogenics. Mr. Kennedy joined Histogenics in 2013 with responsibilities over manufacturing, technology development and quality operations related to clinical development of its flagship product NeoCart, which is a tissue engineered autologous cartilage product. Histogenics is focusing on developing commercial manufacturing infrastructure in the US and Japan in anticipation of successful filing and approval of its NeoCart BLA. Most recently Mr. Kennedy has been focused on leveraging Histogenics' translational capabilities into other tissue engineering product applications. Mr. Kennedy has more than 30 years of experience in biologics manufacturing and process development, including 18 years at Genzyme Corporation. As Genzyme’s Senior Vice President of Biologics Technical Operations, he developed cGMP biologics manufacturing operations at facilities in Belgium and France, oversaw Genzyme’s gene therapy operation in San Diego, and formed the global Biologics Operations organization. Mr. Kennedy has a B.S. from the University of Michigan, an M.S. from the University of Rochester and an M.B.A. from Boston University.